抗TNF治疗后发生结核的RA患者恢复生物制剂的安全性
韩国健康保险数据库起始队列纳入4638例以TNFI为首个生物制剂的RA患者,随访8542人年,结核发病率为1.10/100人年,初始6个月后最高为1.56/100人年。81例发生结核者中30例(37.0%)恢复生物制剂,平均间隔3.3个月,观察45.7人年期间检出2例结核。
要点
- RA患者起始TNFI后结核发病率为1.10/100人年,初始6个月后最高。
- 发生结核后恢复生物制剂者占37.0%,平均间隔3.3个月。
- 恢复生物制剂后需警惕结核复发,本队列30例中检出2例。
核心结论
- RA患者起始TNFI后结核发病率为1.10/100人年,初始6个月后最高,恢复生物制剂需密切监测结核复发。
主要发现
- 共纳入4638例RA患者,贡献8542人年随访,结核发病率为1.10(CI: 0.86-1.34)/100人年。
- 初始6个月后结核发病率最高为1.56(CI: 1.02-2.10)/100人年,随后逐渐下降。
- 81例发生结核的患者中,30例(37.0%)恢复生物制剂,平均间隔3.3个月。
- 30例恢复生物制剂者观察45.7人年期间检出2例结核。
关键数值与推荐
- 结核发病率1.10(CI: 0.86-1.34)/100人年。
- 初始6个月后结核发病率1.56(CI: 1.02-2.10)/100人年。
- 恢复生物制剂平均间隔3.3个月,37.0%患者恢复。
临床怎么用
- RA患者起始TNFI后应关注结核风险,尤其初始6个月后。
- 发生结核后恢复生物制剂需个体化评估并密切监测结核复发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To estimate the incidence of tuberculosis (TB) in rheumatoid arthritis (RA) patients treated with tumor necrotizing factor inhibitor (TNFI) and evaluate the safety of resuming biologic disease-modifying anti-rheumatic drugs (DMARDs) in patients who developed TB after anti-TNF treatment. METHODS: We conducted an inception cohort study of RA patients in the Korean Healthcare Claims Database who started TNFI as the first biologic DMARD between January 2009 and December 2013. The incidence rate (IR) of TB was estimated among total TNFI starters and a nested case-control analysis was performed to compare the characteristics of patients who developed TB and those did not. Patients diagnosed with relapsed TB after resuming biologic DMARDs were identified and their features were described. RESULTS: We included 4638 RA patients who started TNFI, contributing 8542 PYs of follow-up. The IR of TB in TNFI users was 1.10 (CI: 0.86-1.34) per 100 PYs. After the initial 6 months, the IR was highest at 1.56 (CI: 1.02-2.10) and decreased gradually over time. Among the 81 patients who developed TB, 30 patients (37.0%) resumed biologic DMARDs with a mean interval of 3.3 months after TB development. Two cases of TB were detected among 30 patients with an observational period of 45.7 PY. CONCLUSIONS: The IR of TB in RA patients who started TNFI was 1.10 per 100 PYs. This rate was highest during the first 6 months. Resumption of biologic DMARDs requires careful monitoring for TB relapse.
引用
- Cho SK, Kim D, Won S, et al. Safety of resuming biologic DMARDs in patients who develop tuberculosis after anti-TNF treatment. Semin Arthritis Rheum. 2017. PMID: 28216194. doi:10.1016/j.semarthrit.2017.01.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。